This marks the inaugural report of Tandyukisin as an EGFR inhibitor, although its anti-tumor properties were previously identified in a study by Takeshi Yamada’s group in 2015, which isolated a new decalin derivative from the marine sponge Halichondria okadai (Yamada et al., 2015). This evidence concerns the gene EGFR and neoplasm.